The U.S. Food and Drug Administration has approved Tremfya (guselkumab) for the treatment of adults with moderately to ...

Japanese researchers now demonstrate for the first time that the interleukin (IL)-23–IL-17 axis is essential for brain inflammation after stroke. “Macrophages infiltrating the site produce IL ...

Interleukin-23 (IL-23) is one such immune factor that fights infections but is also implicated in many of these inflammatory diseases. However, it was unknown why IL-23 is sometimes beneficial ...

2024年8月30日上午，恒瑞医药在自身免疫疾病领域上市的首个创新药夫那奇珠单抗注射液（安达静）由复旦大学附属华山医院徐金华教授开出全国首张处方，这标志着夫那奇珠单抗正式进入临床应用，打破了同类进口药物的长期垄断局面，为中国银屑病患者带来治疗新选择。

Approval of the dual-acting interleukin (IL)-23 inhibitor in ulcerative colitis was based on findings from QUASAR, an ongoing ...

The US Food and Drug Administration (FDA) has approved Tremfya (guselkumab) for the treatment of adults with moderately to ...

Interlukin-23 inhibitors and interlukin-12/23 inhibitors for patients with psoriasis were not associated with a significant risk for PsA.

The FDA has approved Tremfya® (guselkumab) for the treatment of adult patients with moderately to severely active ulcerative colitis (UC).

Alumis, a recent IPO, has ESK-001, a promising phase 3 TYK2 inhibitor for Psoriasis and SLE, showing superior efficacy and safety over existing treatments. ESK-001's allosteric inhibition offers high ...

Taltz treats these conditions by blocking the action of a specific immune system protein called interleukin 17A (IL-17A). People with these forms of psoriasis and arthritis often have high levels ...

Sickness-induced sleep is a behavior conserved across species that promotes recovery from illness, yet the underlying mechanisms are poorly understood. Here, we show that interleukin-6-like cytokine ...